RT Journal Article T1 A compendium answering 150 questions on COVID-19 and SARS-CoV-2. A1 Riggioni, Carmen A1 Comberiati, Pasquale A1 Giovannini, Mattia A1 Agache, Ioana A1 Akdis, Mübeccel A1 Alves-Correia, Magna A1 Antó, Josep M A1 Arcolaci, Alessandra A1 Azkur, Ahmet Kursat A1 Azkur, Dilek A1 Beken, Burcin A1 Boccabella, Cristina A1 Bousquet, Jean A1 Breiteneder, Heimo A1 Carvalho, Daniela A1 De Las Vecillas, Leticia A1 Diamant, Zuzana A1 Eguiluz-Gracia, Ibon A1 Eiwegger, Thomas A1 Eyerich, Stefanie A1 Fokkens, Wytske A1 Gao, Ya-Dong A1 Hannachi, Farah A1 Johnston, Sebastian L A1 Jutel, Marek A1 Karavelia, Aspasia A1 Klimek, Ludger A1 Moya, Beatriz A1 Nadeau, Kari C A1 O'Hehir, Robyn A1 O'Mahony, Liam A1 Pfaar, Oliver A1 Sanak, Marek A1 Schwarze, Jürgen A1 Sokolowska, Milena A1 Torres, María J A1 van de Veen, Willem A1 van Zelm, Menno C A1 Wang, De Yun A1 Zhang, Luo A1 Jiménez-Saiz, Rodrigo A1 Akdis, Cezmi A K1 COVID-19 K1 SARS-CoV-2 K1 allergy K1 coronavirus disease 2019 K1 severe acute respiratory syndrome-related coronavirus 2 AB In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease. YR 2020 FD 2020-07-20 LK http://hdl.handle.net/10668/15736 UL http://hdl.handle.net/10668/15736 LA en DS RISalud RD Feb 14, 2025